Olaparib is a new type of poly ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediated a DNA repair mechanism, plays an important role in DNA damage repair and apoptosis, so Ola Pani specific effect on target cell DNA damage repair mechanism, by attacking the carrying BRCA1 and BRCA2 mutation critical vulnerabilities in cancer cells play a role, can be used for breast cancer susceptibility gene (BRCA) mutation and for the maintenance treatment of platinum sensitive recurrent severe ovarian cancer patients.

It is suitable for maintenance treatment of platinum-sensitive adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, as well as metastatic breast cancer with germline mutation of BRCA gene and HER2 negative.
Olaparib is an anti-tumor targeted therapy drug, which kills cancer cells mainly by synthesizing a lethal mechanism. It is mainly used clinically for the treatment of advanced epithelial ovarian cancer.